Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba

Current Oncology

Volumn 18, Issue 5, 2011, Pages

  Ott, C L Baunemann ^a   Ratna, N ^b   Prayag, R ^b   Nugent, Z ^b   Badiani, K ^c   Navaratnam, S ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chemotherapy; Elderly patients; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE;

ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; ELDERLY CARE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MONOTHERAPY; ONCOLOGY; OVERALL SURVIVAL; SURVIVAL TIME;

EID: 80053650376     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
2. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75(suppl 1):191-202. [Erratum in: Cancer 1995;75:2979]
3. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto: Canadian Cancer Society; 2006.
4. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971-8.
5. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-81.
6. Lang K, Marciniak MD, Faries D, et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2009;63:264-70.
7. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004;22:3261-8
8. Bunn PA Jr, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2003;95:341-3.
9. Gridelli C. The elvis trial: a phase iii study of single agent vinorelbine as first-line treatment with advanced non-small cell lung cancer. Oncologist 2001;6(suppl 1):4-7.
10. Fisher RA. Statistical Methods for Research Workers. 13th ed. Edinburgh, U.K.: Oliver and Boyd; 1958.
11. Kaplan FL, Meier P. Non-parametric estimation from incomplete estimation. J Am Stat Assoc 1958;53:457-81.
12. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-46.
13. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with non-small-cell lung cancer. J Clin Oncol 2010;28:2191-7.
14. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999;91:66-72.
15. Altundag O, Stewart DJ, Fossella FV, et al. Many patients 80 years and older with advanced non-small cell lung cancer can tolerate chemotherapy. J Thorac Oncol 2007;2:141-6.
16. Richardet ME. Treatment of advanced non-small cell lung cancer (nsclc) in patients older than 70 [abstract e18098]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=47785; cited August 6, 2011]
17. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
18. Navaratnam S, Kliewer EV, Butler J, Demers AA, Musto G, Badiani K. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 2010;70:110-15.